去年此时,诺和诺德如日中天。它的“减肥神药”Wegovy和Ozempic引爆全球市场,“GLP-1”一度成为医药和资本市场的热词,公司市值飙升,成为欧洲第一大上市公司,被誉为“欧洲的苹果”。但一年后,剧情急转直下。7月29日,诺和诺德发布严重盈利预警,预计2025年营收和利润将双双下滑,股价暴跌24%,市值蒸发超过600亿欧元,CEO宣布更换。曾经的神药缔造者,为什么会走到这一步?一、从“风口之王...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.